Evidence map›Paper›PMID 41960423›Full record

ArticleNeuro-oncology advances

Tumor recurrence patterns in eloquent glioma after microsurgical resection and adjuvant radiochemotherapy.

Maximilian Schwendner, Stefan Suvak, Sarah Stefanowicz, Benedikt Wiestler, Christian Diehl, Jan C Peeken, Kai Borm, Igor Yakushev, Bernhard Meyer, Jan J Wilkens and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maximilian SchwendnerDepartment of Neurosurgery, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (M.S., S.Su, B.M., S.M.K.).ORCID https://orcid.org/0000-0001-7380-9992
Stefan SuvakDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Sarah StefanowiczDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Benedikt WiestlerDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).ORCID https://orcid.org/0000-0002-2963-7772
Christian DiehlDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Jan C PeekenDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Kai BormDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Igor YakushevDepartment of Nuclear Medicine, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (I.Y.).
Bernhard MeyerDepartment of Neurosurgery, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (M.S., S.Su, B.M., S.M.K.).
Jan J WilkensDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Stephanie E CombsDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).
Sandro M KriegDepartment of Neurosurgery, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (M.S., S.Su, B.M., S.M.K.).
Denise BernhardtDepartment of Radiation Oncology, TUM University Hospital Rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany (S.Su, S.St, B.W., C.D., J.C.P., K.B., J.J.W., S.E.C., D.B.).ORCID https://orcid.org/0000-0001-5231-9097

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Evidence on the influence of eloquent brain areas on the effectiveness and side effects of radio-therapy (RT) remains limited. This study evaluated the relationship between eloquent brain regions, radiation dose, and tumor recurrence patterns in glioma patients. Methods: Preoperative navigated transcranial magnetic stimulation (nTMS) mapping of language and motor function, complemented by nTMS-based tractography, was performed. Magnetic resonance imaging of tumor recurrence was co-registered with RT treatment plans and functional nTMS data. Tumor growth direction, radiation dose to eloquent structures, and clinical outcomes were analyzed. Results: Seventy-two patients with glioblastoma, aged 57.7 ± 14.8 years, were included. Tumor recurrence toward eloquent brain areas, assessed either by volumetric or linear measurements, indicated growth affecting motor function in 68.1% and language function in 79.3% of patients. Following RT, new motor deficits occurred in 3/48 patients (6.3%) and language deterioration in 3/20 (15.0%). The mean dose to the corticospinal tract was 10.1 Gy in patients with motor decline versus 3.7 Gy in those without ( Conclusions: Tumor recurrence toward eloquent brain areas was observed, with high radiation doses to eloquent brain areas being associated with higher rates of neurological deterioration. These findings create an ambiguous situation regarding the application of high radiation doses to the resection cavity facing eloquent brain areas while simultaneously ensuring optimal dose gradients to spare those.

Indexed as

functional imagingglioblastomaradiotherapytherapy-related deficitstumor recurrence

Identifiers

PMID41960423
PMCPMC13058451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.